Table 1. Clinical characteristics of the study population.
| characteristics | controls | MHD without LVH | MHD with LVH |
| Number | 18 | 24 | 40 |
| Men, n(%) | 12(66.7) | 14(58.3) | 26(65) |
| Median age(range) (yr) | 42(27–59) | 46(29–69) | 54(44–85) |
| Cardiovascular history, n(%) | |||
| Myocardial infarction | 0(0) | 1(4.2) | 0(0) |
| PTCA | 0(0) | 1(4.2) | 0(0) |
| CABG | 0(0) | 0(0) | 0(0) |
| Pacemaker | 0(0) | 0(0) | 1(4.2) |
| Hypertension | 0(0) | 22(91.7) | 35(87.5) |
| Diabetes | 0(0) | 0(0) | 6(15) |
| Hypercholesterolemia | 3(17.6) | 2(8.3) | 2(5) |
| Anemia, n(%) | 0(0) | 21(87.5) | 28(70) |
| Renal failure, n(%) | 0(0) | 24(100) | 40(100) |
| Hemodialysis, n(%) | 0(0) | 24(100) | 44(100) |
| Median hemodialysis duration(range) (mo) | - | 81(16–165) | 94(12–306) |
| Laboratory examinations | |||
| Hemoglobin (g/L) | - | 106.8 | 100.9 |
| Product of Ca and Pi (mg2/dl2) | - | 49.4 | 44.9 |
| iPTH (ng/ml) | - | 314.3 | 210.7 |
| Medication, n(%) | |||
| Aspirin | 0(0) | 0(0) | 1(4.2) |
| β-blocker | 0(0) | 8(33.3) | 11(27.5) |
| CCB | 0(0) | 5(20.8) | 18(45) |
| ACEI | 0(0) | 3(12.5) | 5(12.5) |
| ARB | 0(0) | 2(8.3) | 4(10) |
| Statins | 0(0) | 0(0) | 0(0) |
| Warfarin | 0(0) | 0(0) | 0(0) |
PTCA: percutaneous transluminal coronary angioplasty; CABG: coronary artery bypass grafting; β-blocker: β receptor blocker; CCB: calcium-channel blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II type1 receptor blocker.